BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO
- Investigator-led Phase IIa study met its primary endpoint of disease control rate at 12 weeks - BERGEN, Norway, June 5, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that an oral presentation detailing the initial results from a Phase IIa trial evaluating bemcentinib in patients with mesothelioma was presented today at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The abstract, Bemcentinib and pembrolizumab in